Concomitant use may produce severe weakness in patients with myasthenia gravis.
Source: NLP:betamethasone sodium phosphate and betamethasone acetate
Anticholinesterase Agents Interactions
12 interactions on record
Concomitant use may produce severe weakness in patients with myasthenia gravis.
Source: NLP:depo-medrol, lidocaine, isopropyl alcohol
Concomitant use may produce severe weakness in patients with myasthenia gravis.
Source: NLP:dexamethasone
Concomitant use with dexamethasone may produce severe weakness in patients with myasthenia gravis.
Source: NLP:dexamethasone 1.5 mg
Concomitant use may produce severe weakness in patients with myasthenia gravis.
Source: NLP:dexamethasone intensol
Concomitant use may produce severe weakness in patients with myasthenia gravis. Anticholinesterase agents should be withdrawn at least 24 hours before corticosteroid therapy if possible.
Source: NLP:hydrocortisone sodium succinate
Concomitant use with corticosteroids may produce severe weakness in patients with myasthenia gravis.
Source: NLP:lidocaine, kenalog, povidone iodine
Concomitant use may produce severe weakness in patients with myasthenia gravis. Withdraw anticholinesterases 24 hours before initiating corticosteroid therapy if possible.
Source: NLP:methylprednisolone acetate
Concomitant use with corticosteroids may produce severe weakness in patients with myasthenia gravis.
Source: NLP:methylprednisolone sodium succinate
Concurrent use may produce severe weakness in patients with myasthenia gravis; anticholinesterase agents should be withdrawn 24 hours before initiating corticosteroids if possible.
Source: NLP:prednisolone sodium phosphate
Concomitant use may produce severe weakness in patients with myasthenia gravis.
Source: NLP:triamcinolone acetonide
Concomitant use with corticosteroids may produce severe weakness in patients with myasthenia gravis.
Source: NLP:triamcinolone acetonide extended-release injectable suspension